JPWO2020033630A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020033630A5 JPWO2020033630A5 JP2021506559A JP2021506559A JPWO2020033630A5 JP WO2020033630 A5 JPWO2020033630 A5 JP WO2020033630A5 JP 2021506559 A JP2021506559 A JP 2021506559A JP 2021506559 A JP2021506559 A JP 2021506559A JP WO2020033630 A5 JPWO2020033630 A5 JP WO2020033630A5
- Authority
- JP
- Japan
- Prior art keywords
- chain variable
- variable domain
- seq
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 description 57
- 108090000623 proteins and genes Proteins 0.000 description 57
- 125000003275 alpha amino acid group Chemical group 0.000 description 44
- 239000000427 antigen Substances 0.000 description 34
- 102000038129 antigens Human genes 0.000 description 34
- 108091007172 antigens Proteins 0.000 description 34
- 102100012223 KLRK1 Human genes 0.000 description 24
- 101710036390 KLRK1 Proteins 0.000 description 24
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 13
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 13
- 102000004965 antibodies Human genes 0.000 description 11
- 108090001123 antibodies Proteins 0.000 description 11
- 102100015541 FCGR3A Human genes 0.000 description 10
- 101710044656 FCGR3A Proteins 0.000 description 10
- 101710044657 FCGR3B Proteins 0.000 description 10
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000003950 B-Cell Lymphoma Diseases 0.000 description 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 1
- 230000035693 Fab Effects 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000009251 multiple myeloma Diseases 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000001608 potassium adipate Substances 0.000 description 1
- 239000001601 sodium adipate Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862716207P | 2018-08-08 | 2018-08-08 | |
| US62/716,207 | 2018-08-08 | ||
| PCT/US2019/045632 WO2020033630A1 (en) | 2018-08-08 | 2019-08-08 | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021533169A JP2021533169A (ja) | 2021-12-02 |
| JPWO2020033630A5 true JPWO2020033630A5 (es) | 2022-09-09 |
Family
ID=69413838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021506559A Pending JP2021533169A (ja) | 2018-08-08 | 2019-08-08 | Ｂｃｍａ、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびに使用法 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20210317223A1 (es) |
| EP (1) | EP3833392A4 (es) |
| JP (1) | JP2021533169A (es) |
| KR (1) | KR20210043602A (es) |
| CN (1) | CN112823022A (es) |
| AR (1) | AR114544A1 (es) |
| AU (1) | AU2019318083A1 (es) |
| BR (1) | BR112021002072A2 (es) |
| CA (1) | CA3108427A1 (es) |
| CL (1) | CL2021000316A1 (es) |
| CO (1) | CO2021001410A2 (es) |
| EA (1) | EA202190468A1 (es) |
| IL (1) | IL280512A (es) |
| MA (1) | MA53293A (es) |
| MX (1) | MX2021001524A (es) |
| PE (1) | PE20211860A1 (es) |
| SG (1) | SG11202100883SA (es) |
| TW (1) | TW202019479A (es) |
| WO (1) | WO2020033630A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020008336A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. |
| US20230364230A1 (en) * | 2020-09-11 | 2023-11-16 | Engmab Sàrl | Combination therapy for cancer |
| CN117881702A (zh) * | 2021-08-03 | 2024-04-12 | 山东先声生物制药有限公司 | 一种cd16抗体及其应用 |
| US20230203202A1 (en) * | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2604280A3 (en) * | 2008-03-27 | 2013-10-16 | ZymoGenetics, Inc. | Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
| EP2435473B1 (en) * | 2009-05-27 | 2013-10-02 | F.Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| KR101972446B1 (ko) * | 2011-05-27 | 2019-04-25 | 글락소 그룹 리미티드 | Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질 |
| WO2014100490A1 (en) * | 2012-12-19 | 2014-06-26 | Adimab, Llc | Multivalent antibody analogs, and methods of their preparation and use |
| AR095374A1 (es) * | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
| CN107207598B (zh) * | 2014-12-12 | 2020-12-08 | 蓝鸟生物公司 | Bcma嵌合抗原受体 |
| NZ733580A (en) * | 2015-01-02 | 2024-02-23 | Takeda Pharmaceuticals Co | Bispecific antibodies against plasma kallikrein and factor xii |
| PL3331910T3 (pl) * | 2015-08-03 | 2020-05-18 | Engmab Sàrl | Przeciwciała monoklonalne przeciwko ludzkiemu antygenowi dojrzewania limfocytów B (BCMA) |
| CA2995754A1 (en) * | 2015-08-17 | 2017-02-23 | Janssen Pharmaceutica Nv | Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof |
| EP3433281A1 (en) * | 2016-03-21 | 2019-01-30 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| CN110177803A (zh) * | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| AU2018219348A1 (en) * | 2017-02-10 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Proteins binding BCMA, NKG2D and CD16 |
-
2019
- 2019-08-08 BR BR112021002072-1A patent/BR112021002072A2/pt unknown
- 2019-08-08 CA CA3108427A patent/CA3108427A1/en active Pending
- 2019-08-08 SG SG11202100883SA patent/SG11202100883SA/en unknown
- 2019-08-08 WO PCT/US2019/045632 patent/WO2020033630A1/en active Application Filing
- 2019-08-08 CN CN201980066329.9A patent/CN112823022A/zh active Pending
- 2019-08-08 TW TW108128372A patent/TW202019479A/zh unknown
- 2019-08-08 EP EP19848231.7A patent/EP3833392A4/en active Pending
- 2019-08-08 MX MX2021001524A patent/MX2021001524A/es unknown
- 2019-08-08 EA EA202190468A patent/EA202190468A1/ru unknown
- 2019-08-08 AU AU2019318083A patent/AU2019318083A1/en active Pending
- 2019-08-08 MA MA053293A patent/MA53293A/fr unknown
- 2019-08-08 US US17/266,349 patent/US20210317223A1/en active Pending
- 2019-08-08 KR KR1020217006411A patent/KR20210043602A/ko active Search and Examination
- 2019-08-08 PE PE2021000169A patent/PE20211860A1/es unknown
- 2019-08-08 JP JP2021506559A patent/JP2021533169A/ja active Pending
- 2019-08-08 AR ARP190102253A patent/AR114544A1/es unknown
-
2021
- 2021-01-29 IL IL280512A patent/IL280512A/en unknown
- 2021-02-05 CL CL2021000316A patent/CL2021000316A1/es unknown
- 2021-02-08 CO CONC2021/0001410A patent/CO2021001410A2/es unknown
- 2021-12-06 US US17/543,628 patent/US20220089760A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2021098732A5 (es) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP6742245B2 (ja) | 多重特異性抗体 | |
| ES2439802T3 (es) | Anticuerpos tri- o tetraespecíficos | |
| JP2023052214A5 (es) | ||
| JP2018526981A5 (es) | ||
| JP2020507328A5 (es) | ||
| WO2010112194A1 (en) | Antigen-binding polypeptides and multispecific antibodies comprising them | |
| RU2015145719A (ru) | Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения | |
| MX2011013616A (es) | Proteinas biespecificas tetravalentes de union a antigeno. | |
| JP2010532764A5 (es) | ||
| JP2023134618A5 (es) | ||
| FI3582806T3 (fi) | Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja | |
| JPWO2020033702A5 (es) | ||
| JP2020510646A5 (es) | ||
| JP2023106433A5 (es) | ||
| JPWO2019033043A5 (es) | ||
| JPWO2022102768A5 (es) | ||
| JPWO2019157366A5 (es) | ||
| JPWO2020033630A5 (es) | ||
| JPWO2020033587A5 (es) | ||
| JP2020502233A5 (es) | ||
| JP2020533022A5 (es) | ||
| JPWO2021076564A5 (es) |